Selective Estrogen Receptor Degraders (SERDs): A Promising Treatment to Overcome Resistance to Endocrine Therapy in ERα-Positive Breast Cancer.
作者信息
Abdel-Magid Ahmed F
机构信息
Therachem Research Medilab (India) Pvt. Ltd., Jaipur, India.
出版信息
ACS Med Chem Lett. 2017 Oct 31;8(11):1129-1131. doi: 10.1021/acsmedchemlett.7b00424. eCollection 2017 Nov 9.
Abstract
摘要
相似文献
1
Selective Estrogen Receptor Degraders (SERDs): A Promising Treatment to Overcome Resistance to Endocrine Therapy in ERα-Positive Breast Cancer.
ACS Med Chem Lett. 2017 Oct 31;8(11):1129-1131. doi: 10.1021/acsmedchemlett.7b00424. eCollection 2017 Nov 9.
2
Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
Eur J Med Chem. 2019 Jun 15;172:48-61. doi: 10.1016/j.ejmech.2019.03.058. Epub 2019 Mar 26.
3
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
Pharmacol Ther. 2018 Jun;186:1-24. doi: 10.1016/j.pharmthera.2017.12.012. Epub 2017 Dec 28.
4
Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.
J Med Chem. 2015 Jun 25;58(12):4883-7. doi: 10.1021/acs.jmedchem.5b00760. Epub 2015 Jun 3.
5
Selective oestrogen receptor degraders in breast cancer: a review and perspectives.
Curr Opin Oncol. 2019 Sep;31(5):424-429. doi: 10.1097/CCO.0000000000000567.
6
Next-Generation ERα Inhibitors for Endocrine-Resistant ER+ Breast Cancer.
Endocrinology. 2019 Apr 1;160(4):759-769. doi: 10.1210/en.2018-01095.
7
New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons.
ACS Med Chem Lett. 2018 Jul 5;9(8):803-808. doi: 10.1021/acsmedchemlett.8b00106. eCollection 2018 Aug 9.
8
Structural, Thermodynamic, and Kinetic Traits of Antiestrogen-Compounds Selectively Targeting the Y537S Mutant Estrogen Receptor α Transcriptional Activity in Breast Cancer Cell Lines.
Front Chem. 2019 Sep 4;7:602. doi: 10.3389/fchem.2019.00602. eCollection 2019.
9
AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Cell Signal. 2014 May;26(5):1021-9. doi: 10.1016/j.cellsig.2014.01.018. Epub 2014 Jan 24.
10
Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
J Med Chem. 2017 Feb 23;60(4):1325-1342. doi: 10.1021/acs.jmedchem.6b01355. Epub 2017 Feb 10.
引用本文的文献
1
The deubiquitinating enzyme USP1 modulates ERα and modulates breast cancer progression.
J Cancer. 2020 Oct 12;11(23):6992-7000. doi: 10.7150/jca.50477. eCollection 2020.
本文引用的文献
1
A Review of Fulvestrant in Breast Cancer.
Oncol Ther. 2017;5(1):17-29. doi: 10.1007/s40487-017-0046-2. Epub 2017 May 8.
2
Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
Clin Breast Cancer. 2016 Aug;16(4):238-46. doi: 10.1016/j.clbc.2016.03.001. Epub 2016 Mar 12.
3
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.
Bioorg Med Chem Lett. 2015 Nov 15;25(22):5163-7. doi: 10.1016/j.bmcl.2015.09.074. Epub 2015 Oct 3.
4
Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies.
Future Med Chem. 2015 Aug;7(12):1511-9. doi: 10.4155/fmc.15.93. Epub 2015 Aug 26.
Zotero 插件